Indeed, depleting macrophages using CSF1-R-signaling antagonists improved outcomes in human breast cancer xenografts following combination chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil) [63] and in murine PyMT models following paclitaxel treatment [64]. The gene discussed is CSF1R; the disease is breast carcinoma.